We are honored to announce Dr. Jim HU and Dr. Ronald C. Chen have been awarded with competitive peer-reviewed federal funding for the study of two new treatments for Prostate cancer (PCa); stereotactic body radiation therapy (SBRT) and focal therapy. PCa is the most commonly diagnosed solid tumor in American men and the second most common cause of cancer death. Dr. Hu and Dr. Chen worked closely with patient advocates at US Too New York to plan critical research to explore outcomes of contemporary treatments for clinically significant prostate cancer. This research is imperative to the field as most PCa studies lack outcomes for men of color. Read More.